Treating Secondary Infection In A Patient With Severe Tinea Pedis
In our case, we used all appropriate diagnostic, therapeutic and prophylactic tools recommended by many authors to succeed in treatment of the patient. Some authors also recommend treatment with topical amikacin 5% gel (Amikin, Sopharma), Castellani paint and compresses with 2% to 5% acetic acid, which we might add to our treatment approach. In terms of antibiotic treatment, in our opinion, a first-generation quinolone such as ciprofloxacin might be more effective versus the second-generation levofloxacin or third-generation moxifloxacin that cover gram-negative organisms but are more active against gram-positive flora.
In addition, the patient was getting treatment in different wound care facilities for long periods of time with medications such as amoxicillin-clavulanate and antifungal creams that were not covering P. aeruginosa infection. This might lead to antibiotic resistance.
Dr. Moharan is the Former Chief Podiatry Resident at St. John’s Episcopal Hospital in Far Rockaway, N.Y. and Senior Resident at Kennedy University Hospital in Turnersville, N.J.
Dr. Ahmed is a Former Chief Podiatry Resident at Mount Sinai Hospital of Queens, N.Y. and currently a Wound Care Fellow at St. John’s Episcopal Hospital.
Dr. Karpenko is Former Chief Resident at Kingsbrook Jewish Medical Center in Brooklyn, N.Y. and is currently practicing in Brooklyn.
1. Gentles JC. The isolation of dermatophytes from the floors of communal bathing places. J Clin Pathol. 1956; 9(4):374-7.
2. Resnik SS, Lewis LA, Cohen BH. The athlete's foot. Cutis. 1977; 20(3):351-3,
3. Malcolm B. Tinea pedis. Practitioner. 1998; 242(1584):225.
4. Elewski BE. Cutaneous mycoses in children. Br J Dermatol. 1996; 134(Suppl 46):7-11; discussion 37-8.
5. Ng W, Tan CL, Yeow V, Yeo M, Teo SH. Ecthyma gangrenosum in a patient with hypogammaglobulinemia. J Infect 1998; 36(3):331-5.
6. Pollack M. The virulence of Pseudomonas aeruginosa. Rev Infect Dis. 1984; 6(S6):17-26.
7. Kielhofner M, Atmar RL, Hamill RJ, Musher DM. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis. 1992; 14(2):403-11.
8. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance Systems Report. Am J Infect Control. 2004; 32(4):470-85.
9. Jarvis JG, SkipperJ. Pseudomonas osteochondritis complicating puncture wounds in Children. J Pediatr Orthop. 1994; 14(6):755-9.
10. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am. 2001; 85(1):19-42, v.
11. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999; 43(6):1379-82
12. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother. 1995; 36(Suppl A):135-43.
13. Baltch AL, Griffin PE. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients. Am J Med Sci. 1977; 274(2):119-29.
14. Brewer SC. Clinical investigations in critical care: ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. 1996; 109(4):1020-30.
15. Gupta AK, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol. 2002; 16(6):579-86.
16. Pellizzari C. Recherche sur Trichophyton tonsurans. G Ital Mal Veneree. 1888; 29:8.
17. Douidar SM, Snodgrass WR. Potential role of fluoroquinolones in pediatric infections. Rev Infect Dis. 1989; 11(6):878-89.